Intech Investment Management LLC Raises Stake in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO)

Intech Investment Management LLC boosted its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) by 40.7% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 28,248 shares of the biopharmaceutical company’s stock after purchasing an additional 8,170 shares during the quarter. Intech Investment Management LLC’s holdings in Agios Pharmaceuticals were worth $928,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also bought and sold shares of AGIO. Erste Asset Management GmbH purchased a new position in shares of Agios Pharmaceuticals during the third quarter valued at approximately $97,199,000. Vestal Point Capital LP bought a new position in Agios Pharmaceuticals during the 3rd quarter valued at approximately $33,767,000. State Street Corp raised its stake in Agios Pharmaceuticals by 10.2% during the third quarter. State Street Corp now owns 2,331,433 shares of the biopharmaceutical company’s stock valued at $103,586,000 after buying an additional 216,484 shares during the last quarter. Frazier Life Sciences Management L.P. boosted its holdings in Agios Pharmaceuticals by 19.7% in the third quarter. Frazier Life Sciences Management L.P. now owns 1,044,154 shares of the biopharmaceutical company’s stock worth $46,392,000 after acquiring an additional 172,180 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its holdings in Agios Pharmaceuticals by 36.4% in the third quarter. Loomis Sayles & Co. L P now owns 612,366 shares of the biopharmaceutical company’s stock worth $27,208,000 after acquiring an additional 163,503 shares in the last quarter.

Agios Pharmaceuticals Stock Down 4.3 %

Shares of NASDAQ AGIO opened at $31.30 on Monday. The firm’s 50-day moving average price is $33.38 and its 200-day moving average price is $41.28. Agios Pharmaceuticals, Inc. has a 52-week low of $27.14 and a 52-week high of $62.58. The company has a market cap of $1.79 billion, a PE ratio of 2.76 and a beta of 0.90.

Agios Pharmaceuticals (NASDAQ:AGIO) last issued its earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.74) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by ($0.05). Agios Pharmaceuticals had a negative return on equity of 2.51% and a net margin of 1,845.92%. As a group, equities research analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Insider Activity

In other news, insider Tsveta Milanova sold 2,804 shares of the firm’s stock in a transaction on Monday, January 6th. The shares were sold at an average price of $32.18, for a total transaction of $90,232.72. Following the sale, the insider now directly owns 18,906 shares in the company, valued at $608,395.08. This trade represents a 12.92 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 4.93% of the company’s stock.

Wall Street Analysts Forecast Growth

AGIO has been the subject of several analyst reports. StockNews.com downgraded Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, February 14th. Scotiabank raised their price objective on shares of Agios Pharmaceuticals from $53.00 to $75.00 and gave the company a “sector outperform” rating in a research note on Monday, December 9th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Wednesday, December 18th. Royal Bank of Canada increased their price target on shares of Agios Pharmaceuticals from $55.00 to $57.00 and gave the company an “outperform” rating in a report on Tuesday, December 10th. Finally, HC Wainwright began coverage on shares of Agios Pharmaceuticals in a report on Monday, February 24th. They issued a “buy” rating and a $58.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $56.57.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.